These findings highlight the complexity of the CXCL12/CXCR4 axis, which can contribute to disease pathogenesis in SLE and offer therapeutic benefits in T1D, suggesting that blanket targeting of this axis may not be universally beneficial. The gene discussed is CXCL12; the disease is systemic lupus erythematosus.